Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Applicability of perfusion-weighted imaging in evaluating the curative effect of endostar combined with neoadjuvant chemotherapy in advanced cervical cancer

Zihan Ma , Li Zhao, Jifang Qian, Shengfang Xu, Dalin Zhu

Medical Imaging Center, Gansu Provincial Maternity and Child-care Hospital, Lanzhou 730050, China;

For correspondence:- Zihan Ma Email: mzh_e0028@126.com Tel:+8618609400470

Accepted: 27 November 2023 Published: 31 December 2023

Citation: Ma Z, Zhao L, Qian J, Xu S, Zhu D. Applicability of perfusion-weighted imaging in evaluating the curative effect of endostar combined with neoadjuvant chemotherapy in advanced cervical cancer. Trop J Pharm Res 2023; 22(12):2517-2523 doi: 10.4314/tjpr.v22i12.14

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the applicability of perfusion-weighted imaging (PWI) in evaluating the curative effect of endostar (EN) combined with neoadjuvant chemotherapy (NAC) in advanced cervical cancer.

Methods: Between January 2021 and December 2022, 85 patients from Gansu Provincial Maternity and Child-care Hospital, China with advanced cervical cancer received NAC intravenously and underwent pre and post-chemotherapy PWI. Neoadjuvant chemotherapy (NAC) consisted of paclitaxel (135 - 175 mg/m²) and carboplatin (300 - 400 mg/m²). The NAC regimen comprised three courses, with each course lasting three weeks. General data, gross tumor volume (GTV), maximum signal intensity loss rate (MSILR), tumor regression rate (TRR), and post-chemotherapy MSILR reduction were compared between effective and non-effective groups.

Results: There was a significant difference in International Federation of Gynecology and Obstetrics (FIGO) staging, pathological types and proportion of lymph node metastasis between effective and non-effective groups (p < 0.05). At the end of 3 cycles of chemotherapy, ORR was 72.94 %. After treatment with EN combined with NAC, GTV and MSILR in effective group were significantly lower compared to non-effective group (p < 0.05). After chemotherapy, the mean relative ratio (MRR) and MSILR in effective group were significantly higher compared to non-effective group (p < 0.05). Also, MSILR before treatment (EN combined with NAC) was positively correlated with TRR after chemotherapy in patients with advanced cervical cancer (p < 0.05).

Conclusion: Perfusion-weighted imaging effectively changes tumor volume in patients with advanced cervical cancer after treatment with EN combined with NAC, and this has high application in evaluating the drug’s curative effect.

Keywords: Perfusion-weighted imaging, Endostar, Neoadjuvant chemotherapy, Advanced cervical cancer, Maximum signal intensity loss rate